Member Info for Patagucci

Hi everyone. I’ve recently started looking into the company. Little confused with the financial statements so can someone tell me if I am correct here.
Revenue has greatly increased this year to 4.9million, but the overall loss also increased to -2K. Total current assets 22 million and cash in the bank 1.3 million.

This company has a market cap of 59 million. Am I correct in saying it is currently the company isn’t profitable then… with not a large cash reserve how long can this company continue to operate like this? Is it expecting more profits this year? Sorry I’m still learning about the company so I apologise for my ignorance. Thanks.

Very irrational. I’m happy to wait though, no reason as of now to believe this won’t go up significantly. An RNS away.

I can see how polygon are at 15.341%
But where it says
Name:
1. Aurora Nominee Ltd
2. Natixis
3. Jeffries International Limited
4. JPMorgan Chase Bank, N.A.

Can someone explain what this means, I presume there are other shareholders? But it doesn’t show their % holdings?

I think the consensus is the last few days have been a pump and dump, I disagree, it’s been overbought and a few have tried to capitalise. But this isn’t a share I’d want to dump. Too many upcoming catalysts to loose out on.

I know it’s impossible to say, but what is your personal price target for this?

You say 770 sample size isn’t big enough, but isn’t Synairgen sample size for both P3 trials less than this?

Don’t get me wrong, this isn’t good news. But if synairgen has less adverse affects and a similar success rate, this is still the drug to beat. Inhaled drug also has advantages over pills.
Also which will be more effective against future respiratory viruses. I’ll hold on to my shares for now.

Oxford Scientist have found a gene linked to an increased risk of respiratory failure from COVID. They found that a "relatively unstudied gene called LZTFL1" appears to stop cells in the airways and lungs from responding to the virus properly, potentially leading to respiratory failure and death.

Imagine if this was to do with INF-B. Now that would be huge.

Makes a nice change. Hopefully the first of many!

Sorry that last message was written at the same time as my first response but my phone died… just be sent again now, please ignore. Thanks for your reply.

Andybe4, I was actually unaware of Heberon until now. INF alpha and beta are different I presume. And SNG is given via nebuliser, is Heberon? Would be interested to know how effective it has been. A quick google search doesn’t seem to give to much information about it.

I believe INF Alpha is different to INF Beta, and the drug delivery being inhaled as with SNG is different to Heberon... but still interesting. Didn't know Cuba had interferon!

I’m a new investor to this stock. Big gamble. Seems to be desperate for an RNS to give this some life, seems overdue though so I’ll be holding for the next 2 months and then reevaluate.

I saw someone write that earlier, made me laugh… but then think. P3 trials have 600+ people enrolled. I guess the question isn’t only if phase 3 will be successful, but also, how effective Synairgen actually is. Reducing deaths by 50%, 95%?
I personally don’t think anyone can realistically predict the SP right now, £5? £10? £50? It’s impossible to say and I think people using technical analysis on this stock might as well get into astrology. Results is what will ultimately determine the price of this stock, but the price will be dependent on not just a successful P3, but also by how effective the drug really is. That is what will determine the commercial potential of Synairgen.
Until those results come, I’ll sit back and avoid checking my phone every 5 minutes.

Lukasz Redziniak, Chairman of the Board of the Company, purchased on 28 October 2021 an aggregate of 342,000 Ordinary Shares in the Company at an average price of 2.16 pence per Ordinary Share. Following the purchase, Mr. Redziniak's total shareholding in the Company comprises 720,000 Ordinary Shares, representing 0.0631% per cent of the Issued Share Capital of the Company.

Always good seeing board members buying more shares. Hopefully we all make a good return on our investments.